GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achilles Therapeutics PLC (STU:698) » Definitions » Institutional Ownership

Achilles Therapeutics (STU:698) Institutional Ownership : 0.30% (As of Jun. 23, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Achilles Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Achilles Therapeutics's institutional ownership is 0.30%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Achilles Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Achilles Therapeutics's Float Percentage Of Total Shares Outstanding is 0.00%.


Achilles Therapeutics Institutional Ownership Historical Data

The historical data trend for Achilles Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achilles Therapeutics Institutional Ownership Chart

Achilles Therapeutics Historical Data

The historical data trend for Achilles Therapeutics can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 0.27 0.27 0.27 0.27 0.27 0.27 0.27 0.30 0.30 0.30

Achilles Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Achilles Therapeutics (STU:698) Business Description

Traded in Other Exchanges
Address
245 Hammersmith Road, London, GBR, W6 8PW
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing novel cancer immunotherapies targeting clonal neoantigens. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.

Achilles Therapeutics (STU:698) Headlines

No Headlines